Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 points (p
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
On 6ix: 6ix.com/news/praxis-precision-medicines-announces-positive-topline-results-two-pivotal-phase-3
Praxis Precision Medicines, Inc. on 6ix
In the deck
Story so far
- Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
- Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
- Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Earlier from Praxis Precision Medicines
- ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update
- Praxis Precision Medicines to Participate in September Investor Conferences
- Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
- Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
- Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
Later from Praxis Precision Medicines
- Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
- Praxis Precision Medicines to Participate in Upcoming Investor Conferences
- Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
- Praxis Precision Medicines to Participate in Upcoming Fireside Chat
- Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
Follow Praxis Precision Medicines into a list and get an email when it puts out news.
Follow Praxis Precision Medicines